Variants of the S49 mouse lymphoma cell line exhibit multiple lesions along the pathway of cyclic AMP generation in response to beta(2)-adrenergic stimulation. Two such variants, beta(p) and beta(d), are characterized by decreased receptor binding and mRNA expression, 50% and 25% of wild-type receptor expression, respectively. The rate of beta(2)-adrenergic receptor synthesis was measured and found to be decreased in the beta d cells vis-a-vis the rate in wild type cells. The molecular mass of the beta(2)-adrenergic receptor in the S49 wild-type, beta(p) and beta(d) variant cells was estimated by labeling the receptor with the photoaffinity probe [I-125]iodocyanopindololdiazirine. Receptor size was found to be 67 000 and 47 000 Da in the wild-type and 60 000 and 42 000 in the two variant cells. This 6 kDa discrepancy in mass was abolished upon treatment of labeled cell extracts with N-glycosidase F, suggesting the possibility of either N-terminal truncation or altered glycosylation of the receptor in the variant cells. To distinguish between these possibilities, we sequenced the beta(2)-adrenergic receptor gene and two kilobases of the 5'-non-coding region. No differences were found in the coding region of the gene from wild-type, beta(p) and beta(d) S49 cells suggesting that both the diminished expression and the decreased size of beta(2)-adrenergic receptor in the beta(p) and beta(d) S49 variants are related to impaired glycosylation of the receptor. This hypothesis was substantiated by the reduced retention of the variant cells' beta(2)-adrenergic receptor on immobilized WGA. Furthermore, growth of the S49 cells in the presence of the alpha-mannosidase II inhibitor, swainsonine, preferentially impaired the ability of the receptors derived from the variant cells to bind to WGA. These results imply that altered expression and glycosylation of G-protein-linked receptors occur as a consequence of one or more mutations outside the receptor's open reading frame. (C) 1997 Elsevier Science B.V.